Table 2.
Treatment outcomes at 12 months
| Treatment | No of patients responding | Response rate (% (95% CI)) |
|---|---|---|
| Treatment success (GOS 1 or 2)—intention to treat | ||
| Eradication group (n=145) | 72 | 50 (42 to 58) |
| Placebo group (n=149) | 54 | 36 (28 to 44) |
| Difference | 14 (2 to 25), P=0.02* | |
| Treatment success (GOS 1 or 2)—all evaluable patients | ||
| Eradication group (n=133) | 72 | 54 (46 to 63) |
| Placebo group (n=134) | 54 | 40 (32 to 49) |
| Difference | 14 (1 to 26), P=0.03* | |
| Patients completely asymptomatic (GOS=1)—intention to treat | ||
| Eradication group (n=145) | 41 | 28 (21 to 36) |
| Placebo group (n=149) | 22 | 15 (9 to 20) |
| Difference | 13 (4 to 24), P=0.008* | |
| Treatment success of reflux predominant dyspepsia subgroup—intention to treat | ||
| Eradication group (n=54) | 23 | 43 (29 to 56) |
| Placebo group (n=53) | 17 | 32 (20 to 45) |
| Difference | 11 (NT) | |
| Treatment success of non-reflux predominant dyspepsia subgroup—intention to treat | ||
| Eradication group (n=91) | 49 | 54 (44 to 64) |
| Placebo group (n=96) | 37 | 39 (29 to 48) |
| Difference | 15 (NT) | |
GOS=global overall symptom score; NT=not tested.
*
Statistical comparison by Cochran-Mantel-Haenszel test.